DeLLphi 303; tarla + CPI as maintenance after induction chemoIO; toxicity as expected based on known profile of agents; impressive mDOR, PFS and OS, p3 justified #WCLC24

I contacted my lawmakers about the need for robust federal funding for the NIH, NCI, and ARPA-H. Join me! #ASCOAdvocacy asco.quorum.us/campaign/45495

#WCLC24 Highlights #CommunityOncology: 1. #HARMONi2 in mNSCLC 2. #CM77TvsCM816 resectable NSCLC 3. #TROPIONLung01 in 2L mNSCLC 4. #SKIPPirr: AEs for Amivantamab 5. #TNM staging: 9th Ed 6. Personal highlights #lcsm #OncTwitter IASLC 1/7

Grateful for the opportunity to present our #impsci research on sustainability! UF Health Cancer Center

Excited to be invited as a panelist for the #LEAD24 conference for women in oncology. Do register and join us later this month! #WomeninMedicine bioascend.com/lead-agenda?ga…

Social media is no longer “new” - but there are still *lots* of novel ways to think about its use is healthcare communication for #oncology. Can’t wait for the thought provoking conversations & collaborative work that I know will come out of this mtg. #COSMO24

FDA approves subcutaneous form of atezolizumab for use where IV already approved (including NSCLC and SCLC). Based on IMscin001 showing OS, RR, PROs, safety were similar with far shorter administration time. targetedonc.com/view/fda-appro…

It’s here. The ADRIATIC trial of durvalumab consolidation for LS-SCLC Now published in NEJM. David R. Spigel, MD, FASCO nejm.org/doi/full/10.10…

.Stephen V Liu, MD discusses ADRIATIC 59% received PCI. Durva benefit stands. PRIMALUNG & MAVERICK will answer PCI Q. RT schedule: durva benefit stands and better OS for BID may be due to selection bias. Cisplatin outcomes more puzzling. But does not change chemo practice. #ESMO24

Brilliantly discussed by Stephen V Liu, MD both SCLC abstracts: subgroup analysis of ADRIATIC and anti-flucosyl-GM1 #ESMO24 #LCSM

Day 1 #ESMO24 Highlights #CommunityOncology 1. #TiNivo2 ≥2L mRCC Toni Choueiri, MD 2. #LITESPARK005: 2L mRCC Brian Rini, MD 3. #DB12: Her2+ brain Mets Breast Ca Nancy Lin, MD 4. #ADRIATIC: LS-SCLC 5. #PandasProdige44: Panc Ca 1/6 #lcsm #OncTwitter ESMO - Eur. Oncology OncoAlert #gism #bcsm

🚨🚨Hot off the press NEJM In a randomized Ph II Ponsegromab, an anti-GDF15 mAB, increased weight gain, overall physical activity and reduced cachexia symptoms in patients with #cachexia and ⬆️ GDF-15 nejm.org/doi/full/10.10…

5 year OS rates by PD-L1 expression Marina Garassino #ESMO24 ▪️PD-L1 <1%: 10% ▪️PD-L1 1-49%: 20% ▪️PD-L1 >50%: 30%

POTENTIAL; Neoadjuvant nivo in high risk Stage 1 resectable NSCLC; 3x2w infusions pre op. N52; An impressive pCR 23% MPR 46%; no unexpected AE’s; #ESMO24 ; an excellent and clinically relevant hypothesis generating study

One of the criticisms of LAURA at ASCO24 was we didn’t know the staging details: how many had PET staging? We now know- 55% and importantly the strong and meaningful benefit is still there in PET staged (HR=0.24), reinforcing strong osi benefit. #ESMO24 ESMO - Eur. Oncology

Devika Das, M.D., who cares for patients with thoracic malignancies and works to boost lung #cancer screening rates, has joined UF Medicine and will lead the clinical research agenda for the UF Health Cancer Center's thoracic oncology disease group: go.ufl.edu/wmdy7hk #LCSM

FDA approves first-line pembrolizumab plus platinum + pemetrexed (up to 6 cycles) for advanced malignant pleural #mesothelioma. Based on KEYNOTE-483 (IND 227) that showed adding pembrolizumab improved OS (HR 0.79). fda.gov/drugs/resource…

Updated materials for download/order for AJCC v9 Staging for Thoracic Malignancies. Great resources I keep saved on my phone and in my white coat pocket ⁦IASLC⁩ iaslc.org/research-educa…

Act now. tell our lawmakers to fix this. 👇🏻👇🏻👇🏻 #advocacy #ASCOACT

Its here! U.S. FDA guidance on Conducting Clinical Trials With Decentralized Elements is out! Protocols should specify whether - Telehealth visits is appropriate - Local health care providers can conduct study visits fda.gov/regulatory-inf…